Safety and immunogenicity of two octavalent pneumococcal conjugate vaccines in American Indian infants

Vaccine

Volumn 22, Issue 9-10, 2004, Pages 1260-1264

  Eick, Angelia ^a   Croll, Janné ^a   Weatherholtz, Robert ^a   Croll, Larry ^a   Santosham, Mathuram ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

American Indian; Immunogenicity; Pneumococcal conjugate vaccine

Indexed keywords

ANTIBODY; DIPHTHERIA TOXIN; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

AMERICAN INDIAN; ANOREXIA; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIARRHEA; DROWSINESS; DRUG CONJUGATION; DRUG SAFETY; EDEMA; ENZYME IMMUNOASSAY; ERYTHEMA; HARDNESS; HUMAN; IMMUNOGENICITY; INFANT; INJECTION PAIN; IRRITABILITY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; NEWBORN; NORMAL HUMAN; OPEN STUDY; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SEROTYPE; STREPTOCOCCUS INFECTION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, BACTERIAL; DIPHTHERIA TOXOID; ERYTHEMA; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; INFANT; MALE; PILOT PROJECTS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; TETANUS TOXIN; VACCINES, CONJUGATE;

EID: 1542360813     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.09.026     Document Type: Article

References (25)

1. Cortese M.M., Wolff M., Almeido-Hill J., Reid R., Ketcham J., Santosham M. High incidence of invasive pneumococcal disease in the White Mountain Apache population. Arch. Intern. Med. 152:1992;2277-2282.
2. Käyhty H., Åhman H., Rönnberg P., Tillikainen R., Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugated vaccine is immunogenic in infants and children. J. Infect. Dis. 172:1995;1273-1278.
3. Dagan R., Melamed R., Zamir O., Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr. Infect. Dis. J. 16:1997;1053-1059.
4. Åhman H., Käyhty H., Tamminen P., Vuorela A., Malinoski F., Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well tolerated and able to induce an antibody response in infants. Pediatr. Infect. Dis. J. 15:1996;134-139.
5. Åhman H., Käyhty H., Lehtonen H., Leroy O., Froeschle J., Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr. Infect. Dis. J. 17:1998;211-216.
6. Leach A., Ceesay S.J., Banya W.A., Greenwood B.M. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr. Infect. Dis. J. 15:1996;333-339.
7. Pichichero M.E., Shelly M.A., Treanor J.J. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr. Infect. Dis. J. 16:1997;72-74.
8. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180:1999;1171-1176.
9. Anderson E.L., Kennedy D.J., Geldmacher K.M., Donnelly J., Mendelman P.M. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J. Pediatr. 128:1996;649-653.
10. Miernyk K.M., Parkinson A.J., Rudolph K.M.et al. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years. Clin. Infect. Dis. 31:2000;34-41.
11. Obaro S.K., Adegbola R.A., Chang I.et al. Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr. Infect. Dis. J. 19:2000;463-469.
12. Wuorimaa T., Kayhty H., Leroy O., Eskola J. Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. Vaccine. 19:2001;1863-1869.
13. Wuorimaa T., Dagan R., Eskola J.et al. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr. Infect. Dis. 20:2001;272-277.
14. Nurkka A., Ahman H., Yaich M., Eskola J., Kayhty H. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine. 20:2001;194-201.
15. Sigurdardottir S.T., Ingolfsdottir G., Davidsdottir K.et al. Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine. Pediatr. Infect. Dis. J. 21:2002;548-554.
16. Puumalainen T., Zeta-Capeding M.R., Kayhty H.et al. Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants. Pediatr. Infect. Dis. J. 21:2002;309-314.
17. Rennels M.B., Edwards K.M., Keyserling H.L.et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 101:1998;604-611.
18. Shinefield H.R., Black S., Ray P.et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 18:1999;757-763.
19. Black S., Shinefield H., Fireman B.et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19:2000;187-195.
20. Hausdorff W.P., Bryant J., Paradiso P.R., Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use. Part I. Clin. Infect. Dis. 30:2000;100-121.
21. O'Brien KL, Croll J, Parkinson AJ, Reid R, Santosham M. Active laboratory-based surveillance for invasive Streptococcus pneumoniae (Pneumococcus) among Navajo people in the American southwest, 1989-1996. In: Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 26-29 September 1999. Washington, DC: American Society for Microbiology; 1999 [abstract 1187].
22. Butler J.C., Breiman R.F., Lipman H.B., Hofmann J., Facklam R.R. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J. Infect. Dis. 171:1995;885-889.
23. Jodar L., Butler J., Carlone G.et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 21:2003;3265-3272.
24. Proceedings of the Consulatation Meeting on WHO Guidelines for Production and Quality Control of Pneumococcal Conjugate Vaccines, Geneva, 4-5 June; 2003.
25. Stata (computer program), Version 7.0. College Station, TX: Stata Corporation; 2000.